Global Blood Therapeutics Inc. [NASDAQ: GBT] traded at a low on 12/02/20, posting a -7.06 loss after which it closed the day’ session at $44.78. The company report on December 2, 2020 that GBT Initiates Early Access Program for Voxelotor in Patients with Sickle Cell Disease in Europe and Other Regions Outside the United States.
Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) announced the initiation of an early access program for voxelotor, in Europe and other regions outside the United States, for the treatment of hemolytic anemia in sickle cell disease (SCD) patients ages 12 years and older.
“With no currently approved therapies outside the United States to treat hemolytic anemia in sickle cell disease, the unmet need in this devastating disease is profound,” said Ted W. Love, M.D., president and chief executive officer of GBT. “As part of our deep, long-term commitment to patient access worldwide, we are pleased to initiate this early access program for eligible patients who may benefit from voxelotor.”.
The results of the trading session contributed to over 2603518 shares changing hands. Over the past one week, the price volatility of Global Blood Therapeutics Inc. stands at 5.62% while the volatility over the past one month is 6.27%.
The market cap for GBT stock reached $2.70 billion, with 61.57 million shares outstanding and 54.91 million shares in the current float. Compared to the average trading volume of 1.32M shares, GBT reached a trading volume of 2603518 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Global Blood Therapeutics Inc. [GBT]?
Raymond James have made an estimate for Global Blood Therapeutics Inc. shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on November 06, 2020. While these analysts kept the previous recommendation, Evercore ISI raised their target price to Outperform. The new note on the price target was released on October 06, 2020, representing the official price target for Global Blood Therapeutics Inc. stock. Previously, the target price had yet another raise to $115, while Raymond James analysts kept a Outperform rating on GBT stock.
The Average True Range (ATR) for Global Blood Therapeutics Inc. is set at 3.05, with the Price to Sales ratio for GBT stock in the period of the last 12 months amounting to 31.94. The Price to Book ratio for the last quarter was 6.03, with the Price to Cash per share for the same quarter was set at 8.81.
How has GBT stock performed recently?
Global Blood Therapeutics Inc. [GBT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.78. With this latest performance, GBT shares dropped by -14.66% in over the last four-week period, additionally sinking by -30.90% over the last 6 months – not to mention a drop of -38.23% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GBT stock in for the last two-week period is set at 43.88, with the RSI for the last a single of trading hit 47.19, and the three-weeks RSI is set at 43.41 for Global Blood Therapeutics Inc. [GBT]. The present Moving Average for the last 50 days of trading for this stock 52.22, while it was recorded at 45.52 for the last single week of trading, and 61.63 for the last 200 days.
Global Blood Therapeutics Inc. [GBT]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Global Blood Therapeutics Inc. [GBT] shares currently have an operating margin of -13737.38 and a Gross Margin at -373.43. Global Blood Therapeutics Inc.’s Net Margin is presently recorded at -12654.93.
Return on Total Capital for GBT is now -44.58, given the latest momentum, and Return on Invested Capital for the company is -41.12. Return on Equity for this stock declined to -46.33, with Return on Assets sitting at -37.74. When it comes to the capital structure of this company, Global Blood Therapeutics Inc. [GBT] has a Total Debt to Total Equity ratio set at 25.54. Additionally, GBT Total Debt to Total Capital is recorded at 20.34, with Total Debt to Total Assets ending up at 18.56. Long-Term Debt to Equity for the company is recorded at 25.22, with the Long-Term Debt to Total Capital now at 20.09.
Reflecting on the efficiency of the workforce at the company, Global Blood Therapeutics Inc. [GBT] managed to generate an average of -$757,858 per employee. Receivables Turnover for the company is 1.60 with a Total Asset Turnover recorded at a value of 0.00.Global Blood Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 7.20 and a Current Ratio set at 7.60.
Earnings analysis for Global Blood Therapeutics Inc. [GBT]
With the latest financial reports released by the company, Global Blood Therapeutics Inc. posted -1.59/share EPS, while the average EPS was predicted by analysts to be reported at -1.24/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -28.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GBT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Global Blood Therapeutics Inc. go to 37.00%.
Insider trade positions for Global Blood Therapeutics Inc. [GBT]
There are presently around $2,885 million, in the hands of institutional investors. The top three institutional holders of GBT stocks are: FMR LLC with ownership of 6,660,208, which is approximately -27.135% of the company’s market cap and around 1.70% of the total institutional ownership; PERCEPTIVE ADVISORS LLC, holding 5,800,996 shares of the stock with an approximate value of $259.77 million in GBT stocks shares; and BANK OF AMERICA CORP /DE/, currently with $250.21 million in GBT stock with ownership of nearly 1.904% of the company’s market capitalization.
Positions in Global Blood Therapeutics Inc. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 125 institutional holders increased their position in Global Blood Therapeutics Inc. [NASDAQ:GBT] by around 7,372,006 shares. Additionally, 127 investors decreased positions by around 7,912,343 shares, while 31 investors held positions by with 49,135,983 shares. The mentioned changes placed institutional holdings at 64,420,332 shares, according to the latest SEC report filing. GBT stock had 31 new institutional investments in for a total of 1,146,159 shares, while 51 institutional investors sold positions of 2,667,287 shares during the same period.